106 related articles for article (PubMed ID: 3658828)
1. Percutaneous transperineal placement of gold 198 seeds for treatment of carcinoma of the prostate.
Crusinberry RA; Kramolowsky EV; Loening SA
Prostate; 1987; 11(1):59-67. PubMed ID: 3658828
[TBL] [Abstract][Full Text] [Related]
2. Use of percutaneous transperineal 198Au seeds to treat recurrent prostate adenocarcinoma after failure of definitive radiotherapy.
Loening SA; Turner JW
Prostate; 1993; 23(4):283-90. PubMed ID: 8259342
[TBL] [Abstract][Full Text] [Related]
3. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
[TBL] [Abstract][Full Text] [Related]
4. Survival of patients with localized prostate cancer treated with percutaneous transperineal placement of radioactive gold seeds: stages A2, B, and C.
Hochstetler JA; Kreder KJ; Brown CK; Loening SA
Prostate; 1995 Jun; 26(6):316-24. PubMed ID: 7784271
[TBL] [Abstract][Full Text] [Related]
5. A nomogram to compensate for intraoperative prostate edema during transperineal brachytherapy.
Potters L; Wang XH; Yamada Y
Tech Urol; 2000 Jun; 6(2):99-103. PubMed ID: 10798808
[TBL] [Abstract][Full Text] [Related]
6. Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II clinical trial.
Stromberg J; Martinez A; Gonzalez J; Edmundson G; Ohanian N; Vicini F; Hollander J; Gustafson G; Spencer W; Yan Di
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):161-71. PubMed ID: 7543891
[TBL] [Abstract][Full Text] [Related]
7. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report.
Martinez AA; Pataki I; Edmundson G; Sebastian E; Brabbins D; Gustafson G
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):61-9. PubMed ID: 11163498
[TBL] [Abstract][Full Text] [Related]
8. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
9. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.
Merrick GS; Butler WM; Galbreath RW; Lief JH
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):41-8. PubMed ID: 11516849
[TBL] [Abstract][Full Text] [Related]
10. Conformal prostate brachytherapy: initial experience of a phase I/II dose-escalating trial.
Martinez A; Gonzalez J; Stromberg J; Edmundson G; Plunkett M; Gustafson G; Brown D; Yan D; Vicini F; Brabbins D
Int J Radiat Oncol Biol Phys; 1995 Dec; 33(5):1019-27. PubMed ID: 7493828
[TBL] [Abstract][Full Text] [Related]
11. Transperineal percutaneous iridium-192 implant of the prostate.
Khan K; Crawford ED; Johnson EL
Int J Radiat Oncol Biol Phys; 1983 Sep; 9(9):1391-5. PubMed ID: 6885551
[TBL] [Abstract][Full Text] [Related]
12. Brachytherapy with transperineal (125)Iodine seeds for localized prostate cancer.
Blank LE; Gonzalez Gonzalez D; de Reijke TM; Dabhoiwala NF; Koedooder K
Radiother Oncol; 2000 Dec; 57(3):307-13. PubMed ID: 11104891
[TBL] [Abstract][Full Text] [Related]
13. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
14. Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients.
Sharkey J; Chovnick SD; Behar RJ; Perez R; Otheguy J; Solc Z; Huff W; Cantor A
Urology; 1998 May; 51(5):796-803. PubMed ID: 9610594
[TBL] [Abstract][Full Text] [Related]
15. Pathologic evidence of dose-response and dose-volume relationships for prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy.
Kestin LL; Goldstein NS; Vicini FA; Mitchell C; Gustafson GS; Stromberg JS; Chen PY; Martinez AA
Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):107-18. PubMed ID: 12182980
[TBL] [Abstract][Full Text] [Related]
16. Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy.
Prestidge BR; Bice WS; Kiefer EJ; Prete JJ
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1111-5. PubMed ID: 9539566
[TBL] [Abstract][Full Text] [Related]
17. High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report.
Mate TP; Gottesman JE; Hatton J; Gribble M; Van Hollebeke L
Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):525-33. PubMed ID: 9635698
[TBL] [Abstract][Full Text] [Related]
18. Fiducial markers implanted during prostate brachytherapy for guiding conformal external beam radiation therapy.
Welsh JS; Berta C; Borzillary S; Sam C; Shickell D; Nobile L; Greenberg M; Weiss S; Detorie N
Technol Cancer Res Treat; 2004 Aug; 3(4):359-64. PubMed ID: 15270586
[TBL] [Abstract][Full Text] [Related]
19. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
[TBL] [Abstract][Full Text] [Related]
20. Favorable Preliminary Outcomes for Men With Low- and Intermediate-risk Prostate Cancer Treated With 19-Gy Single-fraction High-dose-rate Brachytherapy.
Krauss DJ; Ye H; Martinez AA; Mitchell B; Sebastian E; Limbacher A; Gustafson GS
Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):98-106. PubMed ID: 27979460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
